• About
  • Offices
  • Careers
  • Students
  • Alumni
Background Image
Logo Bennett Jones
  • People
  • Expertise
  • Resources
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

FEATURED AREAS

Energy
Funds & Finance
Mining
Capital Projects
All Industries
Crisis & Risk Management
Environmental, Social & Governance
Governmental Affairs & Public Policy
All Practices
Insights
Media
Events
Subscribe
COVID-19 Resource Centre
Business Law Talks Podcast
Kickstart
New Energy Economy Series
People
Featured Areas
All Practices
All Industries
About
Offices
Careers
Insights
Events
Search
Search
 

Biotech, Pharma & Lifesciences

  • Download PDF
  • Key Contacts
  • Recent Experience
  • Insights, News & Events
  • Download PDF
  • Recent Experience
  • Insights, News & Events

Biotechnology relies on continuous innovation, an ability to obtain and sustain funding for research and development, and having the intellectual property protection in place to exploit and market new inventions and processes. Bennett Jones is an active, committed advisor to the biotechnology industry, serving the medical, energy and consumer products sectors.

Our team of lawyers, patent agents and trademark agents brings extensive technical knowledge and advanced degrees in the life sciences to the wide range of issues affecting the sector. We provide support on intellectual property protection and enforcement, commercialization of new products and processes, venture capitalization and financing, and government regulation. Possessing excellent relationships with regulatory, contracting and grant-making authorities as well as leading academic institutions and angel and venture capital networks, our goal is to provide industry participants with clear, concise legal counsel that advances mutual interests and maximizes the value of clients' tangible and intangible assets.

Our clients are located in thriving research centres across Canada and around the world, and include start-ups, incubators, Centres for Excellence, clinical and diagnostic research laboratories and private and public companies involved in the development and production of biomedical products and devices. On their behalf, we have negotiated a variety of funding arrangements, drafted joint venture, development, licensing and transfer agreements, prepared and prosecuted patent applications, managed domestic and international patent portfolio applications and handled various enforcement proceedings both domestically and internationally relating to patent infringement, anti-counterfeiting and protection of trade secrets.

Key Contacts

  • Ian M. Goldberg Ian M. Goldberg, Partner
  • Dominique T. Hussey Dominique T. Hussey, Vice Chair and Toronto Managing Partner
  • Related Lawyers

Recent Experience

Skandinaviska Enskilda Banken AB (publ), as joint lead arranger and joint bookrunner in term loan facilities totalling $385 million and $125 million revolving credit facility made to a corporation in the medical technology industry.
United Active Living Inc., in matters related to ownership and operations of assisting living housing projects.
Kensington Capital Partners and Kensington Private Equity Fund in the $35-million acquisition and related financing through its portfolio company, Clearpoint Health Network Inc., of the surgical and medical centres business of Centric Health Corporation, a TSX listed company, and subsequent reorganization of Clearpoint . [Kensington Capital Advisors Inc. is a leading independent investor in alternative assets with over $1.5 billion invested in private equity and alternative assets.]
Emerald Health acquires Québec-based Licensed Producer Agro-Biotech.
48North Cannabis Corp., in its go-public transaction with Kramer Capital Corp.
FV Pharma Inc., in its amalgamation with Century Financial Capital Group.
Canadian counsel to Baker Technologies, Inc., a Colorado-based provider of cannabis-specific customer relationship management software, in its business combination with Santé Veritas Holdings Inc., Briteside Holdings, LLC and Sea Hunter Therapeutics, LLC.
Fluorinov Pharma Inc., a privately-held oncology company, in its $10-million acquisition by Trillium Therapeutics Inc.
Indiva Limited, in its completed $60-million reverse takeover transaction, resulting in the company's listing on the TSX Venture Exchange which was supported by a $23-million financing.
Lead counsel to Harvest One Cannabis, a global cannabis company servicing both the medical and recreational cannabis markets, in Canada and internationally, in their $60 million Canadian listing which was supported by a $25 million financing, and in $65 million of subsequent bought deal financings.
Wheaton Income (formerly Cannabis Wheaton Income Corp.), in its purchase of all of the issued and outstanding shares of RockGarden Medicinals (2014) Inc.
Teva Pharmaceutical Ltd., as Canadian counsel, in its acquisition of ratiopharm Group for approximately $4.85 billion (€3.625 billion).
NUCRYST Pharmaceuticals Corp., in the possible sale of all or substantially all of the assets of NUCRYST and the consideration of an amalgamation of the NUCRYST with 1499642 Alberta Ltd., a wholly-owned subsidiary of The Westaim Corporation.
Oncolytics Biotech Inc., in $13.8-million cross-border public offering of common shares.
Inyx Inc., in the acquisition of certain assets and business of Aventis Pharmaceuticals Puerto Rico Inc.
Protana Inc. (biotechnology), counsel to debtor, in its $40-million debt in the Companies' Creditors Arrangement Act proceedings.
Takeda Chemical Industries Limited, in a class action proceeding and individual claim litigation relating to an alleged agreement to fix prices of vitamins throughout Canada.
Matco Investments Limited, in the reorganization of Synsorb Biotech Inc. into an energy company - Hawker Energy Inc., acquisition of assets into Southward Energy Limited and related financings, valued at $170 million.
MDS Proteomics Inc., (biotechnology), counsel to debtor, in its $100-million debt, in the Companies' Creditors Arrangement Act proceedings.
NUCRYST Pharmaceuticals Corporation and The Westaim Corporation, in NUCRYST's US$45 million cross-border initial public offering, which was concurrently offered in Canada and the United States.
Valens Pharma Ltd., (formerly known as CardioMetabolics Inc.), in a brokered private placement offering of common shares for proceeds of $2.78 million led by Canaccord Capital Corporation.
Valens Pharma Ltd., (formerly known as CardioMetabolics Inc.), in a brokered private placement offering of common shares for proceeds of $4.1 million led by Canaccord Capital Corporation.

Insights, News & Events

Articles

Balancing Privacy and Convenience in Electronic Healthcare Law Review

November 2020
       

Blog

COVID-19 Medical Devices: Fast-Tracking Authorizations

May 07, 2020
       

Updates

Introducing the U.S.-Mexico-Canada Agreement (USMCA)

October 04, 2018
       

Blog

Funding Arrangements in Private Litigation Are Private Matters—Not to Be Scrutinized by the Federal Court or the Defendant

September 22, 2017
       

Blog

Pharma and Biologic Disputes in Canada – New Regulations Take Effect September 21, 2017

September 14, 2017
       

Blog

Pharma and Biologics Disputes in Canada—Big Changes for Big and Small Molecule Litigation

July 20, 2017
       

Blog

Four Key Takeaways from the Lift Cannabis Expo

June 07, 2017
       

Updates

Highly Confidential Data—A Cybersecurity Risk for Cannabis Related Businesses

April 12, 2017
       

Blog

Task Force Report: Branding and Packaging of Cannabis

March 24, 2017
       

In the News

Anne McLellan in Globe and Mail on Medical Marijuana

March 23, 2017
       

Blog

Task Force Report: International Trade Law Implications of Legalization

March 07, 2017
       

Blog

Court Reminds Arbitrators and Employers: Proper Investigation of Employee Medical Marijuana Use is a High Priority

January 19, 2017
       

Blog

A Wise Decision: Recent Lessons on Evidence in Class Actions

December 15, 2016
       

Blog

Association Alone Does Not Equal Causation in Product Liability Cases

December 02, 2016
       

Blog

Shoot to Kill: Expert Bias is an Issue of Admissibility – Wise v. Abbott Laboratories, Limited (Part 1)

December 01, 2016
       

Blog

Trumpian Logic Fails in Recent Pharma Class Action Decision

December 01, 2016
       

Blog

Pharmaceutical Product Liability Class Action Filed Relating to Olmetec Drug

November 25, 2016
       

Blog

PMRA Proposes to Phase Out Uses of Neonic Pesticide in Canada

November 25, 2016
       

Articles

Chambers Practice Guides Life Sciences

November 25, 2016
       

Publications Section

Applicability of GST on Medical Marijuana Obtained under the MMPR

July 26, 2016
       

Blog

Environmental Interest Groups Challenge Registrations of Neonicotinoid Products in Federal Court

July 07, 2016
       

The firm that businesses trust with their most complex legal matters.

  • Privacy Policy
  • Disclaimer
  • Terms of Use

© Bennett Jones LLP 2021 All rights reserved. Bennett Jones refers collectively to the Canadian legal practice of Bennett Jones LLP and the international legal practices and consulting activities of various entities which are associated with Bennett Jones LLP

Logo Bennett Jones